133 related articles for article (PubMed ID: 35906852)
1. Dramatic response to entrectinib in a patient with malignant peripheral nerve sheath tumor harboring novel SNRNP70-NTRK3 fusion gene.
Kobayashi H; Makise N; Shinozaki-Ushiku A; Zhang L; Ishibashi Y; Ikegami M; Tsuda Y; Kohsaka S; Ushiku T; Oda K; Miyagawa K; Aburatani H; Mano H; Tanaka S
Genes Chromosomes Cancer; 2023 Jan; 62(1):47-51. PubMed ID: 35906852
[TBL] [Abstract][Full Text] [Related]
2. Beyond "Triton": Malignant Peripheral Nerve Sheath Tumors With Complete Heterologous Rhabdomyoblastic Differentiation Mimicking Spindle Cell Rhabdomyosarcoma.
Hornick JL; Nielsen GP
Am J Surg Pathol; 2019 Oct; 43(10):1323-1330. PubMed ID: 31107719
[TBL] [Abstract][Full Text] [Related]
3. Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics.
Sugita S; Aoyama T; Emori M; Kido T; Takenami T; Sakuraba K; Terai K; Sugawara T; Tsujiwaki M; Hasegawa T
Diagn Pathol; 2021 Aug; 16(1):79. PubMed ID: 34461930
[TBL] [Abstract][Full Text] [Related]
4. The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements.
Suurmeijer AJ; Dickson BC; Swanson D; Zhang L; Sung YS; Huang HY; Fletcher CD; Antonescu CR
Genes Chromosomes Cancer; 2019 Nov; 58(11):739-746. PubMed ID: 31112350
[TBL] [Abstract][Full Text] [Related]
5.
Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
[TBL] [Abstract][Full Text] [Related]
6. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract][Full Text] [Related]
7. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
8. Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status.
Makise N; Sekimizu M; Kubo T; Wakai S; Hiraoka N; Komiyama M; Fukayama M; Kawai A; Ichikawa H; Yoshida A
Am J Surg Pathol; 2018 May; 42(5):656-664. PubMed ID: 29309298
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors.
Otsuka H; Kohashi K; Yoshimoto M; Ishihara S; Toda Y; Yamada Y; Yamamoto H; Nakashima Y; Oda Y
Pathol Res Pract; 2018 Mar; 214(3):417-425. PubMed ID: 29482987
[TBL] [Abstract][Full Text] [Related]
10. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
[TBL] [Abstract][Full Text] [Related]
11. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
[TBL] [Abstract][Full Text] [Related]
12. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
13. A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Li J; Liu L; Zhang Q; Huang Y; Zhang Y; Gan X; Liu S; Yue Z; Wei Y
Medicine (Baltimore); 2020 Jun; 99(26):e20725. PubMed ID: 32590748
[TBL] [Abstract][Full Text] [Related]
14. A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors.
Owosho AA; Estilo CL; Huryn JM; Chi P; Antonescu CR
Head Neck Pathol; 2018 Jun; 12(2):151-159. PubMed ID: 28762137
[TBL] [Abstract][Full Text] [Related]
15. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
[TBL] [Abstract][Full Text] [Related]
16. Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors.
Thangaiah JJ; Westling BE; Roden AC; Giannini C; Tetzlaff M; Cho WC; Folpe AL
Ann Diagn Pathol; 2022 Aug; 59():151967. PubMed ID: 35567887
[TBL] [Abstract][Full Text] [Related]
17. H3K27 trimethylation loss in malignant peripheral nerve sheath tumor: a systematic review and meta-analysis with diagnostic implications.
Lu VM; Marek T; Gilder HE; Puffer RC; Raghunathan A; Spinner RJ; Daniels DJ
J Neurooncol; 2019 Sep; 144(3):433-443. PubMed ID: 31342317
[TBL] [Abstract][Full Text] [Related]
18. Role of Histone H3K27 Trimethylation Loss as a Marker for Malignant Peripheral Nerve Sheath Tumor in Fine-Needle Aspiration and Small Biopsy Specimens.
Mito JK; Qian X; Doyle LA; Hornick JL; Jo VY
Am J Clin Pathol; 2017 Aug; 148(2):179-189. PubMed ID: 28898989
[TBL] [Abstract][Full Text] [Related]
19. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
20. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
